Modern drug discovery is increasingly plagued by both poor solubility and limited permeability. While lipid-based formulations have long been recognized as the gold standard for overcoming bioavailability hurdles, they have traditionally been confined to capsule technologies.

In this whitepaper, Gattefossé Pharmaceuticals seeks to bridge the gap between lipid-based formulations and oral solid dosage forms, demonstrating the utility and potential of incorporating lipid excipients into modern OSD development.

Inside, you will find:

• The Power of Solid Lipids: Learn how Compritol® 888 ATO solves critical OSD challenges, including tablet lubrication, taste-masking, and creating sustained-release matrices that can reduce tablet volume by up to 60%.
• Lipid-Polymer Synergies: Explore how ternary Amorphous Solid Dispersions (ASDs) using Gelucire® and Labrasol® ALF enable stable drug loading, increase in vivo exposure by up to 1.7-fold, and enhance dissolution by 4.5-fold.
• Solidified Solubilizers (Solid SEDDS): Discover the technique of adsorbing liquid SEDDS onto porous carriers to create free-flowing, compressible powders that retain the powerful benefits of liquid formulations.

Novel APIs require innovative solutions. Download the whitepaper below and learn how established lipid chemistries offer a safe, scalable approach to accelerate your next tablet formulation to market.